Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Standard
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. / Pratz, Keith W; Panayiotidis, Panayiotis; Recher, Christian; Wei, Xudong; Jonas, Brian A; Montesinos, Pau; Ivanov, Vladimir; Schuh, Andre C; DiNardo, Courtney D; Novak, Jan; Pejsa, Vlatko; Stevens, Don; Yeh, Su-Peng; Kim, Inho; Turgut, Mehmet; Fracchiolla, Nicola; Yamamoto, Kazuhito; Ofran, Yishai; Wei, Andrew H; Bui, Cat N; Benjamin, Katy; Kamalakar, Rajesh; Potluri, Jalaja; Mendes, Wellington; Devine, Jacob; Fiedler, Walter.
In: BLOOD CANCER J, Vol. 12, No. 4, 71, 20.04.2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
AU - Pratz, Keith W
AU - Panayiotidis, Panayiotis
AU - Recher, Christian
AU - Wei, Xudong
AU - Jonas, Brian A
AU - Montesinos, Pau
AU - Ivanov, Vladimir
AU - Schuh, Andre C
AU - DiNardo, Courtney D
AU - Novak, Jan
AU - Pejsa, Vlatko
AU - Stevens, Don
AU - Yeh, Su-Peng
AU - Kim, Inho
AU - Turgut, Mehmet
AU - Fracchiolla, Nicola
AU - Yamamoto, Kazuhito
AU - Ofran, Yishai
AU - Wei, Andrew H
AU - Bui, Cat N
AU - Benjamin, Katy
AU - Kamalakar, Rajesh
AU - Potluri, Jalaja
AU - Mendes, Wellington
AU - Devine, Jacob
AU - Fiedler, Walter
N1 - © 2022. The Author(s).
PY - 2022/4/20
Y1 - 2022/4/20
N2 - Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
AB - Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects
KW - Bridged Bicyclo Compounds, Heterocyclic
KW - Cytarabine/therapeutic use
KW - Fatigue/etiology
KW - Humans
KW - Leukemia, Myeloid, Acute/drug therapy
KW - Quality of Life
KW - Sulfonamides
U2 - 10.1038/s41408-022-00668-8
DO - 10.1038/s41408-022-00668-8
M3 - SCORING: Journal article
C2 - 35443742
VL - 12
JO - BLOOD CANCER J
JF - BLOOD CANCER J
SN - 2044-5385
IS - 4
M1 - 71
ER -